Skip to Main Content

Try STAT+ TODAY

Sarepta Therapeutics

Most Read

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: FDA official is ‘very comfortable’ with controversial drug approval

Pharmalot Ed Silverman

FDA emails show how upset some officials were over the Sarepta approval

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Senator to hold hearing on Mylan’s Medicaid settlement

Pharmalot Ed Silverman

FDA official warns other drug makers not to copy Sarepta

Pharmalot Ed Silverman

Anthem declines to cover Sarepta drug for Duchenne, citing doubts over data

Pharmalot Ed Silverman

Most insurers unfazed by high price of orphan drugs

Pharmalot Ed Silverman

Doctors expect to prescribe Sarepta’s DMD drug despite insurance concerns

Pharmalot Ed Silverman

FDA commissioner calls for Sarepta drug study to be retracted

All Coverage

Pharmalot Ed Silverman

Sarepta to charge $300K for Duchenne drug. ‘We tried to be reasonable,’ CEO says

Biotech Damian Garde

Did the FDA set ‘a dangerous precedent’ with its latest drug approval?

advertisement

Pharmalot Ed Silverman

Behind the Sarepta drug approval was intense FDA bickering

Pharmalot Ed Silverman

FDA approves Sarepta’s controversial drug for Duchenne muscular dystrophy

Pharmalot Ed Silverman

FDA confirms that critic of Sarepta drug has left the agency

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: Sarepta stock jumps after critic of DMD drug leaves the FDA

Pharmalot Ed Silverman

Hope for Sarepta drug approval? FDA requests more data

Pharmalot Ed Silverman

Sarepta stock dives on speculation FDA is sidestepping a drug approval

Pharmalot Ed Silverman

FDA delays decision on whether to approve Sarepta drug for Duchenne

Pharmalot Ed Silverman

Senators urge FDA to approve Sarepta drug for Duchenne

Pharmalot Ed Silverman

Wall Street betting intensifies over Sarepta’s muscular dystrophy drug

Pharmalot Ed Silverman

FDA panel votes against Sarepta’s drug for Duchenne muscular dystrophy

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: FDA panel reviewing Duchenne muscular dystrophy drug

Pharmalot Ed Silverman

FDA review raises fresh doubts that Sarepta DMD drug will be approved

Pharmalot Ed Silverman

FDA urged to approve Sarepta DMD drug by dozens of medical experts

Pharmalot Ed Silverman

FDA delays decision on Duchenne drug but accepts info from Sarepta

Pharmalot Ed Silverman

Pharmalot, Pharmalittle: ‘Misleading’ sedative video, Duchenne drug meeting delayed